Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Authors
Polański, RadosławHodgkinson, Cassandra L
Fusi, Alberto
Nonaka, Daisuke
Priest, Lynsey
Kelly, Paul
Trapani, Francesca
Bishop, P
White, A
Critchlow, S
Smith, P
Blackhall, Fiona H
Dive, Caroline
Morrow, Christopher J
Affiliation
Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute; Faculty of Life Sciences and Medical and Human Sciences, Manchester Academic Health Sciences Centre, University of ManchesterIssue Date
2014-02-15
Metadata
Show full item recordAbstract
The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase I evaluation in the United Kingdom. AZD3965 is proposed, via lactate transport modulation, to kill tumor cells reliant on glycolysis. We investigated the therapeutic potential of AZD3965 in small cell lung cancer (SCLC) seeking rationale for clinical testing in this disease and putative predictive biomarkers for trial use.Citation
Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. 2014, 20 (4):926-37 Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-13-2270PubMed ID
24277449Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-13-2270
Scopus Count
Collections
Related articles
- Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.
- Authors: Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR
- Issue date: 2017 Jul
- In Vivo Anticancer Activity of AZD3965: A Systematic Review.
- Authors: Silva A, Antunes B, Batista A, Pinto-Ribeiro F, Baltazar F, Afonso J
- Issue date: 2021 Dec 29
- In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model.
- Authors: Guan X, Morris ME
- Issue date: 2020 Jun 11
- MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.
- Authors: Beloueche-Babari M, Wantuch S, Casals Galobart T, Koniordou M, Parkes HG, Arunan V, Chung YL, Eykyn TR, Smith PD, Leach MO
- Issue date: 2017 Nov 1
- Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.
- Authors: Guan X, Rodriguez-Cruz V, Morris ME
- Issue date: 2019 Jan 7